Abstract
We report the virological monitoring and the antiviral therapy adopted for the treatment of a patient affected by chronic B lymphocytic leukemia, who experienced a severe pneumonia with long-term shedding of influenza virus A(H1N1)pdm09, characterized by an early development of oseltamivir resistance.
Keywords:
A(H1N1)pdm09; Chronic lymphocytic leukemia; Influenza virus; Oseltamivir resistance; Triple-combination antiviral drug therapy (TCAD); Zanamivir.
Copyright © 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
MeSH terms
-
Aged
-
Antiviral Agents / pharmacology*
-
Antiviral Agents / therapeutic use
-
Drug Resistance, Viral
-
Drug Therapy, Combination
-
Female
-
Humans
-
Influenza A Virus, H1N1 Subtype / isolation & purification
-
Influenza A Virus, H1N1 Subtype / physiology*
-
Influenza, Human / complications
-
Influenza, Human / drug therapy*
-
Influenza, Human / virology
-
Leukemia, Lymphocytic, Chronic, B-Cell / complications*
-
Oseltamivir / pharmacology
-
Oseltamivir / therapeutic use
-
Pneumonia, Viral / complications
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / virology
-
Treatment Outcome
-
Virus Shedding
-
Zanamivir / pharmacology
-
Zanamivir / therapeutic use
Substances
-
Antiviral Agents
-
Oseltamivir
-
Zanamivir